PGI2 THE BUDGET IMPACT OF TEGASEROD ON A MANAGED CARE ORGANIZATION FORMULARY
3 David Geffen School of Medicine at UCLA, VA Greater Los Angeles Healthcare System, CURE Digestive Diseases Research Center, Los Angeles, CA, USA; 4 Department of Gastroenterology and Hepatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA OBJECTIVE: To develop a budget impact model that assesses the economic impact of adding tegaserod for the management of irritable bowel syndrome with constipation to a managed care organization's (MCO) formulary. METHODS: The model estimates per patient and per-member per-month (PMPM) economic impact of two patient subgroups six-months prior to and sixmonths after the initiation of tegaserod. The incremental budget impact of tegaserod was then calculated by subtracting the prior period costs from the post period costs. The two patient subgroups were 1) females with an IBS diagnosis (FIBS); and 2) males and females with other GI diagnosis (GID). Resource utilization data were based on a retrospective, longitudinal study of 3365 tegaserod users from a large, geographically-diverse MCO utilizing medical and pharmacy administrative claims data. We used prevalence and tegaserod treatment rates observed from the aforementioned MCO. Sensitivity analyses were performed by varying several model inputs parameters.
RESULTS:
The base-case model resulted in an incremental PMPM budget impact associated with the use of tegaserod of $0.01. Total per-patient budget impact (for all resources, including tegaserod) for a six-month period was $274.34 for FIBS and $301.84 for GID. Overall, 25.9% (29.0% for FIBS and 21.9% for GID) of the cost of tegaserod was offset by decreases in resource utilization. Key drivers of post-tegaserod reductions in resource costs were hospital stays, abdominal and pelvic CAT scans, colonoscopies (for FIBS), and outpatient office consultations and emergency room visits (for GID). CONCLUSIONS: Tegaserod therapy can decrease GI-related resource use, resulting in a significant cost-offset percentage. When the associated budget impact of adding tegaserod to formulary is absorbed across an entire MCO population, the PMPM impact of tegaserod is small.
PGI3 THE ECONOMIC IMPLICATIONS OF SOMATROPIN [RDNA ORIGIN] MANAGEMENT IN PATIENTS WITH SHORT BOWEL SYNDROME
Migliaccio-Walle K, Caro JJ, Möller J Caro Research, Concord, MA, USA OBJECTIVES: Short bowel syndrome (SBS) results from extensive surgical removal of portions of the small intestine, and leads to serious morbidity and shortened life expectancy. A recent trial showed that use of somatropin [rDNA origin] for injection (rhGH) significantly reduces the need for standard treatments such as parenteral nutrition (PN), which significantly impair quality of life. This study sought to evaluate the economic impact of this new treatment. METHODS: A discrete event simulation was developed to compare a regimen of daily rhGH for four weeks with PN alone in the management of patients with SBS. Risks of treatment-and disease-related complications and resource use were modeled in two identical cohorts of 1000 patients for two years. Rates of disease-related events (e.g., biliary problems), including age-dependent mortality, were assumed to be the same across strategies. Risk functions for each strategy were estimated from the literature and one randomized clinical trial. Direct medical costs were obtained from Medicaid and the literature. Sensitivity analyses were conducted on key parameters. Direct medical costs are reported in US$2004. All outcomes were discounted at 3%/yr. RESULTS: Overall, 96.0% of patients receiving rhGH reduced or eliminated PN use within six weeks of initiating the regimen; one-third weaned completely; and PN use decreased 2.8 days. PN was estimated to cost $118,099 in year one and $132,935 in year two, totaling $251,033 vs rhGH cost of $84,309, including $17,459 for treatment, in year one, a savings of $33,790 per patient; over two years $165,559, for a total savings of $85,474. Cost neutrality is achieved within eight months. Sensitivity analyses showed no significant change in results. CONCLUSIONS: The reduction of PN use or complete weaning in the vast majority of patients with rhGH results in a substantial savings and improvement in quality of life-a dominant strategy. 4 Albuquerque VA Hospital, Albuquerque, NM, USA Although hepatitis A and B vaccinations are recommended for patients with chronic hepatitis C virus (HCV), the ideal vaccination strategy is not determined. OBJECTIVE: To model the cost-effectiveness of two strategies of vaccinating patients with HCV infection against hepatitis A (HAV) and hepatitis B (HBV) viruses. The strategies evaluated were: universal vaccination with the combined HAV and HBV vaccine, and selective vaccination based on immunity by blood testing. METHODS: A decision tree computer model was constructed to compare the costeffectiveness of the two vaccination strategies from the New Mexico Veterans Affairs Health Care System (NMHAHCS) perspective. A retrospective review of all HCV patients (2542 subjects) at the NMVAHCS was performed to extract prevalence of immunity to HAV and HBV, and prevalence of decompensated liver disease. Literature review was performed to obtain other probabilities for the model. The effectiveness measure was the number of patients immune to both HAV and HBV. RESULTS: The selective strategy was less costly but less effective with a cost-effectiveness ratio of $105 per patient immune to HAV& HBV. The universal strategy was more effective but more expensive with a cost-effectiveness ratio of $112 per patient immune to HAV& HBV. Compared with the selective strategy, universal strategy was associated with an incremental costeffectiveness (ICE) ratio of $154 per additional patient immune to HAV and HBV. The universal strategy would become more cost-effective if the cost of combined vaccine reduces by >9.7% to <$0.75, if the cost of HBV vaccine increases by >25% to >$34.50, if the cost of blood tests for immunity increases by >23% to >$25.25, or if the prevalence of anti-HBs decreases to <24%. CONCLUSIONS: The selective vaccination strategy for HAV and HBV in our sample of patients with HCV is more cost-effective. However, the ICE for the universal strategy is minimal. 3 Hoffmann-La Roche, Nutley, NJ, USA Peginterferon alfa-2a (40KD) (PEGASYS®), a new treatment option for patients infected with chronic hepatitis B (CHB), offers improved efficacy with a defined treatment duration compared with lamivudine (LAM), but at a higher cost. OBJECTIVE: To assess the clinical outcomes, costs and costeffectiveness of PEGASYS for the treatment of patients with HBeAg-negative CHB, compared to LAM treatment for one-year and four-years. METHODS: A cost-effectiveness analysis from the UK National Health Service (NHS) perspective using a statetransition Markov model simulating the natural history of HBeAg-negative CHB. Efficacy data were obtained from a recent, randomized clinical trial comparing PEGASYS and LMV in patients with HBeAg-negative CHB. Patients: Hypothetical cohort of 40-year old patients with HBeAg-negative CHB. Interventions: PEGASYS and LAM monotherapy. Measurements: Life expectancy, quality-adjusted life expectancy, lifetime costs, and incremental cost-effectiveness ratios (ICERs). RESULTS: Fortyeight week treatment with PEGASYS compared to LAM resulted in higher total costs, but greater quality-adjusted life expectancy, yielding an ICER of £5047/quality-adjusted life year (QALY) gained. Although there is uncertainty associated with the prognosis of HBeAg-negative CHB, the ICER did not exceed £10,000/QALY gained despite variation in each parameter used in the analysis. In the analysis comparing 48-week treatment with PEGASYS to 208-week treatment with LAM, the ICER was £2767/QALY gained. CONCLUSIONS: Short-term treatment with PEGASYS compared to either short-term or long-term LAM treatment in CHB patients who are HBeAg-negative appears to offer life expectancy benefits at a cost-effectiveness ratio comparable to other currently reimbursed pharmaceutical interventions.
PGI4 THE COST-EFFECTIVENESS OF TWO STRATEGIES FOR VACCINATING PATIENTS WITH HEPATITIS C VIRUS INFECTION AGAINST HEPATITIS A AND HEPATITIS B

PGI5 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) COMPARED TO LAMIVUDINE FOR THE TREATMENT OF E ANTIGEN NEGATIVE CHRONIC HEPATITIS B IN THE UK
